Stout’s Rudi Moreno on Value Creation During Long Hold Periods
With holding periods now averaging seven years, Stout's Rudi Moreno explores the impact on value creation
Podcasts
ACG’s Middle Market Growth podcast features in-depth interviews with M&A leaders, middle-market dealmakers, and other industry experts covering shifting market conditions, industry trends, and value creation strategies.
Subscribe on Soundcloud, Apple Podcasts, Spotify, or wherever you listen to podcasts.
Interested in joining the podcast as a guest? Contact Kaitlyn Gregorio at kgregorio@acg.org or download the media kit for more information.
Navigating the Competitive Private Credit Market
WhiteHorse Capital's Javier Casillas and Samuel Goldworm discuss staying ahead of the curve in a crowded market
Insights on the Mid-Market Lending Outlook with TPG Twin Brook’s Pete Notter
TPG Twin Brook's Pete Notter discusses the 'fine line' between managing costs and impeding growth
The Cybersecurity Risk of Renewables
As investors flock to the renewable energy sector, Kenny Boyce of Third Party Cyber Security joins the podcast to share some surprising risks in the space
Discussing the Demand for Sustainable Fashion with Wearwell’s Erin Houston
Wearwell cofounder and CEO Erin Houston joins the podcast to discuss the investment opportunity in sustainable fashion
Consulting the Crystal Ball with WhiteHorse Capital
WhiteHorse U.S. executive managing director and CEO Stuart Aronson and president and global head of origination Pankaj Gupta join the Conversations podcast
Delivering Dividends: Investing in Accounting Firms
Koltin Consulting Group dives into the M&A opportunity of accounting firms
Managing Wildfire Risk with AI
As energy companies seek ways to safeguard utility infrastructure, Buzz Solutions is using emerging technologies in innovative ways to help keep fires snuffed
GF Data Report: Q3 Shows Valuations Rebounding
Bob Dunn of GF Data shares the signs hinting at an M&A rebound in Q3
Cell Therapy: A New M&A Frontier
Cellares co-founder and CEO Fabian Gerlinghaus shares his unique approach to developing successful cell therapies
